A phase II evaluation of AMG 706 [motesanib] (IND 79,697) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

Trial Profile

A phase II evaluation of AMG 706 [motesanib] (IND 79,697) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs Motesanib (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Dec 2017 Status changed to discontinued due severe toxicity causing concern for patients
    • 29 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 29 Apr 2011 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top